Table 1.
Breast cancer targets and matched therapeutics.
|
TARGET |
MATCHED THERAPY |
|
|---|---|---|
| Already available | In development | |
| PIK3CA |
α-specific PI3K inhibitor Alpelisib |
Isoform-specific PI3K inhibitors |
| HS-10352 | ||
| Inavolisib | ||
| MEN1611 | ||
| OKI-219 | ||
| RLY-2608 | ||
| STX-478 | ||
| Tenalesib | ||
| TOS-358 | ||
| Dual PI3K and mTOR inhibitors | ||
| Gedatolisib | ||
| AKT | Pan AKT inhibitor | Pan AKT inhibitor |
| Capivasertib | Ipatasertib | |
| ESR1 |
SERD Elacestrant |
SERD |
| Amcenestrant | ||
| Borestrant | ||
| Camizestrant | ||
| Giredestrant | ||
| Imlunestrant, | ||
| Rintodestrant | ||
| Taragarestrant | ||
| BRCA1/2 |
Parp inhibitors Olaparib Talazoparib |
Parp inhibitors |
| Niraparib | ||
| Pamiparib | ||
| Rucaparib | ||
| Veliparib | ||
| HER2 |
Anti-HER2 mAb Trastuzumab Pertuzumab Margetuximab TKIs Lapatinib Neratinib Tucatinib Anti-HER2 ADCs TDM-1 T-DXd |
Anti-HER2 mAb |
| Zanidantamab | ||
| TKIs | ||
| Pyrotinib | ||
| Poziotinib | ||
| Anti-HER2 ADCs | ||
| A166 (ZW49, SHR-A1811) | ||
| ARX788 | ||
| SYD985 | ||
| RC48 | ||
| Anti-HER3 ADCs | ||
| Patritumab deruxtecan (HER3-DXd) | ||
| SHR-A2009 | ||
| PD−1/PD−L1 axis | Pembrolizumab Atezolizumab |
Adebrelimab |
| Camrelizumab | ||
| Cemiplimab | ||
| Dostarlimab | ||
| Durvalumab | ||
| SHR1701 | ||
Abbreviations: ADC, antibody-drug conjugate; mAb, monoclonal antibody; HER2, human epidermal growth factor receptor 2; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
Source: clinicaltrials.gov, as assessed on November 12, 2024